MedImmune Announces Seven Key Promotions and...(ystems to improve the infrastructure of ...)

Date:11/5/2007

ystems to improve the infrastructure of quality assurance operations in support of future growth, for ensuring the company's products meet corporate and government standards and that quality assurance activities comply with applicable regulations, and for providing enhanced expertise and guidance in interpreting government regulations and guidelines. He most recently held positions at GTC Biotherapeutics (formerly known as Genzyme Transgenics Corporation), where he served as vice president of corporate quality, and Stryker Corporation, where he was director of quality assurance. Mr. Maines holds a bachelor of science degree in biology/microbiology from Gannon University.

Management Promotions

As vice president, human resources (HR), Mr. Max Donley is responsible for providing business-integrated leadership and delivering professional tools, programs and services to optimize MedImmune's human capital investments through the HR function across all sites to drive business results. Prior to joining MedImmune in 2000 as a senior manager, he led field HR and development at Bed Bath & Beyond. Mr. Donley, a certified senior professional in human resources through the Society for Human Resource Management, holds a master and a bachelor degree in business administration from George Mason University and the University of Michigan, respectively.

Mr. Jonathan Klein-Evans now serves as vice president, intellectual property, overseeing all intellectual property issues for the company. Throughout his nearly 15 years in the field, Mr. Klein-Evans has worked on all aspects of patent law, including prosecution, litigation, opinions, interferences, oppositions and licensing. He joined MedImmune in 2002 as director, intellectual property. Previously, Mr. Klein-Evans was an in-house patent attorney at Human Genome Sciences, Inc. (HGS). Prior to his tenure at HGS, Mr. Klein-Evans worked for the law firm of Pennie & Edmonds, LLP, first as a law clerk, then a patent agent,
'/>"/>

SOURCE MedImmune, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results